Max Colon Cleanse Digesti Cleanse
On sale on the US market (according to the DSLD)
Health Plus, food supplement from the US market
Max Colon Cleanse Digesti Cleanse (Health Plus), a food supplement au code-barres 083502103486, is described by its US market label. If sold in France, it would be subject to 2 points of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- À vérifier
Serratiopeptidase is listed in the Novel Food Catalogue as a novel food not yet authorised in the European Union: in the form covered by the entry, it should not be sold until authorised. The catalogue is informative; a declaration in France is not an authorisation.
Source: Novel Food Catalogue (status of products under Regulation (EU) 2015/2283), POL-NF-00692.
- Conditions légales
Citrus aurantium L.: La quantité ingérée de p-synéphrine doit être inférieure à 20 mg par dose journalière recommandée. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants, aux femmes enceintes ou allaitantes et en cas de traitement anti-hypertenseur. La caféine et les sources de caféine ne sont pas autorisées dans les compléments alimentaires contenant Citrus aurantium L.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Health Plus
- Barcode
- 083502103486
- Form
- Capsule
- One serving
- 1 capsule
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Gelatin
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Proprietary Digestive Enzyme Blend | Blend | 200 mg |
| Protease | Enzyme | not stated |
| Lipase | Enzyme | not stated |
| Serratiopeptidase | Enzyme | not stated |
| Hemicellulase | Enzyme | not stated |
| Amylase | Enzyme | not stated |
| Chitosanase | Enzyme | not stated |
| Proprietary Herbal Digest Blend | Blend | 300 mg |
| Rice Bran powder | Fibre | not stated |
| Chamomile flower extract | Plant | not stated |
| Aloe | Plant | not stated |
| Burdock | Plant | not stated |
| Cilantro (Coriandrum sativum) | Plant | not stated |
| Fennel | Plant | not stated |
| Parsley (Petroselinum crispum) | Plant | not stated |
| Amla Berry Extract (Phyllanthus emblica) | Plant | not stated |
| Artichoke leaf extract | Plant | not stated |
| Atractylodes Root Extract | Plant | not stated |
| Cardamom seed extract | Plant | not stated |
| Citrus Aurantium (Citrus aurantium) | Plant | not stated |
| Dandelion | Plant | not stated |
| Gentian root extract | Plant | not stated |
| Ginger root extract | Plant | not stated |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Colon Cleanse Max Digesti Cleanse
Entered into DSLD on 21 November 2012. Withdrawn from the US market on 26 May 2015 (according to the DSLD).- Active ingredient removed : Aloe (quantity not stated)
- Active ingredient removed : Amla Berry Extract (quantity not stated)
- Active ingredient removed : Amylase (quantity not stated)
- Active ingredient removed : Artichoke leaf extract (quantity not stated)
- Active ingredient removed : Atractylodes Root Extract (quantity not stated)
- Active ingredient removed : Burdock (quantity not stated)
- Active ingredient removed : Cardamom seed extract (quantity not stated)
- Active ingredient removed : Chamomile flower extract (quantity not stated)
- Active ingredient removed : Chitosanase (quantity not stated)
- Active ingredient removed : Cilantro (quantity not stated)
- Active ingredient removed : Citrus Aurantium (quantity not stated)
- Active ingredient removed : Dandelion (quantity not stated)
- Active ingredient removed : Dandelion (quantity not stated)
- Active ingredient removed : Fennel (quantity not stated)
- Active ingredient removed : Gentian root extract (quantity not stated)
- Active ingredient removed : Ginger root extract (quantity not stated)
- Active ingredient removed : Hemicellulase (quantity not stated)
- Active ingredient removed : Lipase (quantity not stated)
- Active ingredient removed : Parsley (quantity not stated)
- Active ingredient removed : Protease (quantity not stated)
- Active ingredient removed : Rice Bran powder (quantity not stated)
- Active ingredient removed : Serratiopeptidase (quantity not stated)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Serratiopeptidase
Read the warning, when it applies and the studies cited
SERRAPEPTASE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gastrointestinal lesions/ulcers, a kidney or liver disorder, or are having surgery (Bhagat et al. 2013; Chopra et al. 2009; Al- Khateeb and Nusair 2008; Mazzone et al. 1990).
Sources cited by Health Canada (4)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners or anti-inflammatory medications (Bhagat et al. 2013; Chopra et al. 2009; Al-Khateeb and Nusair 2008; Mazzone et al. 1990).
Sources cited by Health Canada (4)
- Al-Khateeb TH and Nusair Y. Effect of the proteolytic enzyme serrapeptase on swelling, pain and trismus after surgical extraction of mandibular third molars. International Journal of Oral Maxillofacial Surgery 2008;37:264-268. PubMed Randomised trial
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
- Chopra D, Rehan HS, Mehra P, et al. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen and betamethasone using the dental impaction pain model. International Journal of Oral Maxillofacial Surgery 2009;38:350-355. PubMed Randomised trial
- Mazzone A, Catalani M, Costanzo M, et al. Evaluation of serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology : a multicentre, double-blind, randomized trial versus placebo. Journal of International Medical Research 1990;18:379-388. PubMed Randomised trial
Known adverse reactions
Stop use if rash, difficulty breathing, hypersensitivity and/or severe allergy occur (Bhagat et al. 2013; Balagi 2007).
Sources cited by Health Canada (1)
- Bhagat S, Agarwal M and Roy V. Serratiopeptidase : A systemic review of the existing evidence. International Journal of Surgery 2013;11(3):209-217 PubMed Systematic review
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
- Amla Berry Extract
Read the warning, when it applies and the studies cited
Amla - Phyllanthus Emblica
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).
Sources cited by Health Canada (1)
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
Applies to products providing more than 3 grams of amla, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).
Sources cited by Health Canada (1)
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
Condition of application: Amlapitta, Digestive tonic.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Laxative.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).
Sources cited by Health Canada (3)
- CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
- Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.
Contraindications
Condition of application: Laxative.
Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).
Sources cited by Health Canada (1)
- HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
Known adverse reactions
Condition of application: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.
When using this product you may experience a laxative effect.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Health Plus
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Max Colon Cleanse Digesti Cleanse (Health Plus): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/83502103486-max-colon-cleanse-digesti-cleanse-health-plus, updated 24 July 2015.